PEGylated IL‐11 (BBT‐059): A Novel Radiation Countermeasure for Hematopoietic Acute Radiation Syndrome

Interleukin-11 was developed to reduce chemotherapy-induced thrombocytopenia; however, its clinical use was limited by severe adverse effects in humans. PEGylated interleukin‐11 (BBT‐059), developed by Bolder Biotechnology, Inc., exhibited a longer half-life in rodents and induced longer-lasting increases in hematopoietic cells than interleukin‐11. A single dose of 1.2 mg kg−1 of BBT‐059, administered subcutaneously to CD2F1 mice (12–14 wk, male) was found to be safe in a 14 d toxicity study. The drug demonstrated its efficacy both as a prophylactic countermeasure and a mitigator in CD2F1 mice exposed to 60Co gamma total-body irradiation. A single dose of 0.3 mg kg−1, administered either 24 h pre-, 4 h post-, or 24 h postirradiation increased the survival of mice to 70–100% from lethal doses of radiation. Preadministration (−24 h) of the drug conferred a significantly (p
Source: Health Physics - Category: Radiology Tags: Papers Source Type: research